Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Guus Scheefhals, Chief Executive Officer ADDRESS Padualaan 8 3584 CH Utrecht The Netherlands TELEPHONE +31 30 253 2668 FAX +31 30 253 7131 EMAIL g.scheefhals@crossbeta.com YEAR FOUNDED 2005 Crossbeta Biosciences B.V. www.crossbeta.com COMPANY PROFILE Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta’s oligomer drug discovery platforms which are accessible for partnering in therapeutics areas such as Alzheimer´s, Parkinson’s, Huntington and Diabetes Type 2. In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity. Stable oligomers can also be used as reference in biomarker assays. MANAGEMENT Guus Scheefhals, Chief Executive Officer Martijn Gebbink, Chief Scientific Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Harry Welten, MBA Chief Financial Officer ADDRESS Cytos Biotechnology AG Wagistrasse 25 CH-8952 Schlieren TELEPHONE Direct phone: +41 44 733 4646 Mobile: +41 79 750 1564 FAX Direct fax: +41 44 733 4702 EMAIL harry.welten@cytos.com YEAR FOUNDED 1995 CYTOS Biotechnology AG www.cytos.com FINANCIAL SUMMARY Cash and cash equivalents per June 30, 2012: CHF 36.1 mln COMPANY PROFILE Cytos Biotechnology is dedicated to the discovery, development and commercialization of a novel class of medicines – called Immunodrugs. Immunodrugs are therapeutic vaccines intended for use in the treatment and prevention of common chronic diseases which afflict millions of people worldwide. The Company’s lead program is CYT003, a novel allergen-independent Immunodrug with disease-modifying potential in Phase II clinical development for allergic asthma, and with potential to treat a broad range of different allergies. MANAGEMENT Dr Thomas Hecht, Executive Chairman Dr Frank Hennecke, EVP Product Development Dr Philipp Müller, EVP Clinical Development Harry Welten, MBA, Chief Financial Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45: CONTACT Mike Romanos PhD Chief Exec
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?